EFPIA


Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros.

PROJECT LEADER
Dr Stefan Jaroch 
Head External Innovation Technologies, Research & Development, Pharmaceuticals

For more information visit pharma.bayer.com


Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 30 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2018, Grünenthal employed around 4,900 people and achieved sales of € 1.3 bn.

PROJECT LEADER
Dr. Sven Kühnert
Head of Research Technologies

For more information visit www.grunenthal.com


Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,700 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (princeps drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. More than 2,000 employees work in our 3 research centers and 19 therapeutic research centers worldwide, from exploratory research to late stage development with particular emphasis on diseases with the greatest need.

Currently 33 drug candidates are in development in diseases such as congestive heart failure, programmed cell death (apoptosis) in cancer cells, immune system (immuno-oncology), Alzheimer disease, autism. Servier has close links with external partners through over 250 partnerships worldwide, including biotechnology companies, public institutions and pharmas. Servier (IdRS) has a long-standing track record of academic collaborations and is strongly developing its partnering activities with Biotech and other Pharmaceutical companies.

PROJECT LEADER
Dr. Jean-Claude Ortuno
Scientific Director, Director in Medicinal Chemistry in charge of Exploratory Projects

For more information visit www.servier.com



Janssen Pharmaceutica NV is a subsidiary of the Janssen Research & Development organization of the Janssen Pharmaceutical companies of Johnson & Johnson (www.jnjpharmarnd.com). We are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time. Our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas: cardiovascular and metabolism, immunology, infectious diseases and vaccines, neuroscience, and oncology. We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships. We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.

PROJECT LEADER
Dr Herman van Vlijmen
Senior Director Computational Chemistry

For more information visit www.janssen.com



AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

PROJECT LEADER
Dr Garry Pairaudeau
Head of External Sciences

For more information visit www.astrazeneca.com 


Merck is a leading German science and technology company with divisions in Healthcare, Life Science and Performance Materials with €14.8 billion sales in 2018 and a history which dates back to 1668. Merck Heathcare (the biopharmaceutical division) is dedicated to explore innovative therapeutic modalities and is committed to the discovery of New Chemical & Biological Entities, using a state-of-the art infrastructure for screening, compound logistics and medicinal chemistry. Merck’s screening is run in 1536 well format in uHTS throughput. The libraries have high purity requirements and are stored in single tubes under argon at -20°C and undergo limited freeze-thaw cycles. The screening department uses a wide range of technologies including confocal imaging. Hit characterization efforts include exclusion of compound assay interference, orthogonal confirmation and selectivity screens.

PROJECT LEADER
Dr Dirk Finsinger
Director Early Pipeline Technologies

For more information visit www.merckgroup.com


Sanofi Aventis is a French multinational pharmaceutical company and the world's sixth-largest by prescription sales. The company´s principal therapeutic areas are: oncology, immunology & inflammation, rare blood disorders, rare and neurologic diseases, diabetes & cardiovascular (DCV) and vaccines.  Sanofi Aventis was formed in 2004 after a merger between Aventis and Sanofi-Synthélabo. 

PROJECT LEADER
Dr Hubert Haag
Sourcing & External Opportunities Lead Identification

For more information visit sanofi.com


UCB is a global biopharmaceutical company with a portfolio of small molecule and antibody based therapies for the treatment of severe immune-mediated diseases and CNS disorders. The firm has approximately 7,500 employees worldwide with operations in around 40 countries. UCB’s key research sites are based in Belgium, the United Kingdom and USA developing an innovative pipeline of novel therapeutics. Core products treat patients with epilepsy, rheumatoid arthritis and Parkinson’s disease. UCB invests internally, externally and via collaboration to continually improve screening capabilities, and access the best external collections and technologies. Expertise covers protein families across the breadth of CNS and Immunology therapeutic areas, and the UCB screening collection reflects this. A strong fragment technology platform includes substantial investment in associated biophysical techniques and the structural biology required for fragment-led programs.

PROJECT LEADER
Dr Jeremy Davis
Director Hit Discovery and Chemistry Partnerships

WORK PACKAGE LEAD (ASSAY DEVELOPMENT)
Dr Céline Vermeiren
Associate Director, Screening Sciences

For more information visit www.ucb.com

 


Former Partners


A global pharmaceutical company with a portfolio of small molecule and antibody based therapies for treating CNS disorders. Core products improve the lives of patients with depression, Alzheimer’s disease and Parkinson’s disease and reach more than 100 countries: sales in 2014 were almost €2 billion. Lundbeck has over 6000 employees worldwide, with more than 1300 in R&D. Further novel medicines to treat diseases within neurology and psychiatry are actively sought to complement previous Lundbeck discoveries, especially those focusing on Alzheimer’s disease, Parkinson’s disease, depression and schizophrenia. The firm has generated novel and innovative small lead structures using HTS, fragment screening and de novo design, which combines with experience in specialist research and in preclinical/clinical development to deliver innovative medicines to patients.

PROJECT LEADER
Dr Klaus Bæk Simonsen
Vice President

For more information visit www.lundbeck.com